Citius Oncology, Inc. (CTOR)

Citius Oncology Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022
Prepaid Expenses	10.01	7.73	2.69
Total Current Assets	10.01	7.73	2.69
Long-Term Deferred Charges	40	40	40
Total Assets	50.01	47.73	42.69
Accounts Payable	-	1.29	0.09
Accrued Expenses	31.39	19.76	5.75
Total Current Liabilities	31.39	21.05	5.85
Long-Term Deferred Tax Liabilities	1.58	1.15	0.58
Total Liabilities	32.98	22.2	6.42
Common Stock	0.01	0.01	0.01
Additional Paid-In Capital	49.49	43.66	41.69
Retained Earnings	-32.47	-18.13	-5.43
Shareholders' Equity	17.03	25.54	36.27
Total Liabilities & Equity	50.01	47.73	42.69
Filing Date Shares Outstanding	67.5	67.5	67.5
Total Common Shares Outstanding	67.5	67.5	67.5
Working Capital	-21.39	-13.31	-3.16
Book Value Per Share	0.25	0.38	0.54
Tangible Book Value	17.03	25.54	36.27
Tangible Book Value Per Share	0.25	0.38	0.54

Source: S&P Capital IQ. Standard template. Financial Sources.